Blau Farmaceutica SA
BOVESPA:BLAU3

Watchlist Manager
Blau Farmaceutica SA Logo
Blau Farmaceutica SA
BOVESPA:BLAU3
Watchlist
Price: 13.66 BRL 0.44%
Market Cap: 2.5B BRL

Profitability Summary

Blau Farmaceutica SA's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Blau Farmaceutica SA

Revenue
1.8B BRL
Cost of Revenue
-1.1B BRL
Gross Profit
688.6m BRL
Operating Expenses
-298.1m BRL
Operating Income
390.5m BRL
Other Expenses
-122.4m BRL
Net Income
268.1m BRL

Margins Comparison
Blau Farmaceutica SA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
BR
Blau Farmaceutica SA
BOVESPA:BLAU3
2.4B BRL
39%
22%
15%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
327.6B USD
71%
30%
7%
US
Amgen Inc
NASDAQ:AMGN
155.7B USD
64%
25%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
134.5B USD
78%
38%
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD
86%
38%
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
AU
CSL Ltd
ASX:CSL
115.6B AUD
52%
26%
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
55.6B USD
87%
29%
32%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.7B USD
86%
-5%
-11%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Blau Farmaceutica SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
BR
Blau Farmaceutica SA
BOVESPA:BLAU3
2.4B BRL
13%
8%
14%
11%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
327.6B USD
88%
3%
17%
20%
US
Amgen Inc
NASDAQ:AMGN
155.7B USD
106%
7%
12%
10%
US
Gilead Sciences Inc
NASDAQ:GILD
134.5B USD
33%
11%
25%
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD
-6%
-4%
21%
94%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
115.6B AUD
15%
7%
12%
9%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
55.6B USD
16%
13%
13%
14%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.7B USD
519%
-7%
-4%
-6%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less